Mushonga mutsva unononotsa kupararira kwegomarara rezamu

Ongororo yakaitwa munguva pfupi yapfuura yezvokurapa yakaratidza kuti mushonga mutsva wegomarara rezamu unogona kuderedza chirwere chacho kwemwedzi mitatu uye kuva nemigumisiro mishoma.

Mushonga wekuyedza, unozivikanwa se "TDM1," unoshanda uchipesana neakanyanya hutsinye rudzi rwegomarara rezamu, uye mushonga "Herceptin" unosanganiswa nechemotherapy mudosi imwe, uye miedzo yakaratidza kuti mushonga mutsva unodzivirira gomarara rezamu repamusoro kubva pakuipa. mwedzi mitatu kana zvichienzaniswa nekurapa kwakajairika, panguva imwe chete, kunoderedza mhedzisiro yekemotherapy inopedza simba.

Mushonga uyu unoonekwa sewekutanga werudzi rwawo kugomarara rezamu uye unoshanda nekubatanidza kune chikamu checarcinogenic cell uye kudzivirira kuti isakura nekupararira, ichienda kuchitokisi panguva imwe chete uye ichiburitsa chepfu chemotherapy kubva mukati. .

Mukuedzwa kwevanhu vangangosvika chiuru vane kenza yepamusoro yeHER2-positive, varwere vana kubva kune gumi vakapindura TDM1, zvichienzaniswa nevasingasviki chikamu chimwe muzvitatu cheavo vaive pakurapa kwakajairwa.

Purofesa Paul Ellis anobva kuGuy's Hospital muLondon akati: "Izvi zvakawanikwa zvakakosha nekuti kekutanga mugomarara rezamu, takakwanisa kuvandudza zvakanyanya kushanda panguva imwe cheteyo tichideredza zvakawanda zvisingafadzi zvinokonzerwa nekemotherapy."

Nekuda kwake, Director weBritish Breast Cancer Research Society, Dr. Lisa Wild Chidzidzo ichi chiitiko chakanaka kune varwere vane gomarara repazamu reHER2 avo parizvino vane nzira dzekurapwa shoma.

Sezvineiwo, gomarara rezamu nderimwe regomarara rinorapika zvachose kana rikaonekwa pachine nguva, uye izvi ndizvo zvatinodaidza kumadzimai ese ane makore makumi maviri nemashanu ekuberekwa.